Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

innoviva inc - INVA

INVA

Close Chg Chg %
21.34 -0.44 -2.06%

Open Market

20.90

-0.44 (2.06%)

Volume: 169.50K

Last Updated:

Sep 9, 2026, 12:14 PM EDT

Trade Now

Company Overview: innoviva inc - INVA

INVA Key Data

Open

$21.16

 Day Range

20.90 - 21.41

52 Week Range

16.52 - 25.15

 Market Cap

$1.54B

Shares Outstanding

72.25M

 Public Float

71.34M

Beta

0.33

 Rev. Per Employee

N/A

P/E Ratio

5.20

 EPS

$4.88

Yield

0.00%

 Dividend

$0.25

EX-DIVIDEND DATE

Sep 8, 2015

 SHORT INTEREST

N/A

AVERAGE VOLUME

617.16K

  

INVA Performance

1 Week
 
 0.05%
 
1 Month
 
 4.05%
 
3 Months
 
 -6.16%
 
1 Year
 
 10.17%
 
5 Years
 
 37.41%
 

INVA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About innoviva inc - INVA

Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

INVA At a Glance

Innoviva, Inc.
1350 Old Bayshore Highway
Burlingame, California 94010
Phone 1-650-238-9600 Revenue 425.13M
Industry Pharmaceuticals: Major Net Income 271.17M
Sector Health Technology 2025 Sales Growth 14.125%
Fiscal Year-end 12 / 2026 Employees 159
View SEC Filings

INVA Valuation

P/E Current 5.196
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 6.055
Price to Sales Ratio 3.986
Price to Book Ratio 1.272
Price to Cash Flow Ratio 8.60
Enterprise Value to EBITDA 6.847
Enterprise Value to Sales 3.285
Total Debt to Enterprise Value 0.193

INVA Efficiency

Revenue/Employee 2,673,761.006
Income Per Employee 1,705,440.252
Receivables Turnover 4.556
Total Asset Turnover 0.286

INVA Liquidity

Current Ratio 14.639
Quick Ratio 13.851
Cash Ratio 11.403

INVA Profitability

Gross Margin 72.335
Operating Margin 38.517
Pretax Margin 76.886
Net Margin 63.784
Return on Assets 18.256
Return on Equity 29.095
Return on Total Capital 18.807
Return on Invested Capital 22.691

INVA Capital Structure

Total Debt to Total Equity 22.937
Total Debt to Total Capital 18.658
Total Debt to Total Assets 16.452
Long-Term Debt to Equity 22.902
Long-Term Debt to Total Capital 18.629
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Innoviva Inc - INVA

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
345.16M 324.26M 372.51M 425.13M
Sales Growth
-14.92% -6.05% +14.88% +14.12%
Cost of Goods Sold (COGS) incl D&A
33.30M 78.34M 76.45M 117.61M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
19.51M 35.70M 39.85M 40.23M
Depreciation
108.00K 121.00K 151.00K 151.00K
Amortization of Intangibles
5.58M 21.78M 25.90M 26.28M
COGS Growth
+140.78% +135.23% -2.42% +53.84%
Gross Income
311.86M 245.92M 296.06M 307.52M
Gross Income Growth
-20.42% -21.14% +20.39% +3.87%
Gross Profit Margin
+90.35% +75.84% +79.48% +72.33%
2022 2023 2024 2025 5-year trend
SG&A Expense
104.86M 132.03M 129.19M 143.77M
Research & Development
41.43M 33.92M 13.65M 30.60M
Other SG&A
63.43M 98.11M 115.54M 113.17M
SGA Growth
+679.41% +25.91% -2.15% +11.28%
Other Operating Expense
- - - -
-
Unusual Expense
173.95M (88.52M) 123.41M (161.59M)
EBIT after Unusual Expense
33.05M 202.41M 43.45M 325.34M
Non Operating Income/Expense
269.69M 10.85M 16.14M 18.22M
Non-Operating Interest Income
6.37M 15.82M 19.14M 21.09M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
15.79M 19.16M 22.21M 16.70M
Interest Expense Growth
-17.21% +21.33% +15.93% -24.81%
Gross Interest Expense
15.79M 19.16M 22.21M 16.70M
Interest Capitalized
- - - -
-
Pretax Income
286.95M 194.10M 37.39M 326.86M
Pretax Income Growth
-35.56% -32.36% -80.74% +774.24%
Pretax Margin
+83.13% +59.86% +10.04% +76.89%
Income Tax
66.69M 14.38M 14.00M 55.70M
Income Tax - Current - Domestic
41.29M 9.98M 26.61M 10.05M
Income Tax - Current - Foreign
- - - 1.79M
-
Income Tax - Deferred - Domestic
25.40M 4.40M (12.62M) 43.85M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
220.26M 179.72M 23.39M 271.17M
Minority Interest Expense
- - - 6.34M
-
Net Income
213.92M 179.72M 23.39M 271.17M
Net Income Growth
-19.53% -15.99% -86.98% +1,059.22%
Net Margin Growth
+61.98% +55.42% +6.28% +63.78%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
213.92M 179.72M 23.39M 271.17M
Preferred Dividends
- - - -
-
Net Income Available to Common
213.92M 179.72M 23.39M 271.17M
EPS (Basic)
3.0716 2.7466 0.3729 4.0235
EPS (Basic) Growth
-5.19% -10.58% -86.42% +978.98%
Basic Shares Outstanding
69.64M 65.44M 62.73M 67.39M
EPS (Diluted)
2.3682 2.202 0.3621 3.3014
EPS (Diluted) Growth
-17.46% -7.02% -83.56% +811.74%
Diluted Shares Outstanding
95.25M 86.88M 74.19M 84.76M
EBITDA
226.51M 149.59M 206.72M 203.97M
EBITDA Growth
-42.25% -33.96% +38.19% -1.33%
EBITDA Margin
+65.62% +46.13% +55.49% +47.98%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 35.50
Number of Ratings 4 Current Quarters Estimate 0.53
FY Report Date 09 / 2026 Current Year's Estimate 2.47
Last Quarter’s Earnings -1.14 Median PE on CY Estimate N/A
Year Ago Earnings 3.30 Next Fiscal Year Estimate 2.305
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 4 3 4
Mean Estimate 0.53 0.53 2.47 2.31
High Estimates 0.57 0.61 2.56 2.83
Low Estimate 0.50 0.46 2.35 1.92
Coefficient of Variance 6.80 12.13 4.38 17.17

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Innoviva Inc - INVA

Date Name Shares Transaction Value
May 7, 2026 Sarah J. Schlesinger Director 140,492 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 7, 2026 Sarah J. Schlesinger Director 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 7, 2026 Jules Haimovitz Director 152,692 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 7, 2026 Jules Haimovitz Director 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 7, 2026 Derek A. Small Director 45,035 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 7, 2026 Derek A. Small Director 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 7, 2026 Marianne Zhen Chief Accounting Officer 58,643 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 7, 2026 Marianne Zhen Chief Accounting Officer 31,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 7, 2026 Mark A. DiPaolo Director 140,492 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 7, 2026 Mark A. DiPaolo Director 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 7, 2026 Pavel Raifeld Chief Executive Officer; Director 285,936 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 7, 2026 Pavel Raifeld Chief Executive Officer; Director 312,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 7, 2026 Stephen Basso Chief Financial Officer 88,007 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 7, 2026 Stephen Basso Chief Financial Officer 93,750 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Innoviva Inc in the News